Would you add a DMARD such as methotrexate for a patient with GCA and partial response to tocilizumab but inability to taper prednisone below 10mg daily?
Alternatively would you change therapy entirely to upadacitinib and consider this a tocilizumab failure?
Community PollStarted
In a patient with giant cell arteritis (GCA) on tocilizumab who has had a partial response but cannot taper prednisone below 10 mg/day, would you add a DMARD such as methotrexate?
20 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Massachusetts General Hospital
Answered on
This is a clinical scenario that comes up relatively frequently, but unfortunately, there is a lack of data to guide this decision, and both approaches are reasonable. On balance, methotrexate has been demonstrated to have a moderate effect with respect to steroid sparing and reducing relapses in GC...
Join for free or sign in to see the full answer